サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1667938

分岐病変市場- 世界の産業規模、シェア、動向、機会、予測、用途別（末梢、冠動脈）、地域別、競合別、2020～2030年

Bifurcation Lesions Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Application (Peripheral, Coronary), By Region, Competition, 2020-2030F

出版日
ページ情報
英文 180 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

分岐病変市場- 世界の産業規模、シェア、動向、機会、予測、用途別（末梢、冠動脈）、地域別、競合別、2020～2030年
出版日: 2025年02月28日
発行: TechSci Research
ページ情報: 英文 180 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

分岐病変の世界市場規模は2024年に27億6,000万米ドルで、予測期間には40億2,000万米ドルに達すると予測され、2030年までのCAGRは6.43%です。

世界の分岐病変市場は、主要動脈が2つの小枝に分かれることで発生する分岐病変の診断と治療に焦点を当てた医療産業の専門セグメントを網羅しています。

市場概要
予測期間 2026-2030
市場規模：2024年 27億6,000万米ドル
市場規模：2030年 40億2,000万米ドル
CAGR：2025年～2030年 6.43%
急成長セグメント 末梢
最大市場 北米

分岐病変の世界市場は、血管、特に冠動脈の分岐病変がもたらす課題に対処することを目的とした医療機器、処置、治療法を扱う。これらの病変は血流を制限し、心血管合併症を引き起こす可能性があります。

主な市場促進要因

心血管疾患の有病率の増加

主な市場課題

分岐病変治療の複雑さ

規制と償還のハードル

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の分岐病変市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 用途別（末梢、冠動脈）
    • 地域別
    • 企業別（2024）
  • 市場マップ

第6章 北米の分岐病変市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の分岐病変市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • 英国
    • イタリア
    • フランス
    • スペイン

第8章 アジア太平洋地域の分岐病変市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • インド
    • 日本
    • 韓国
    • オーストラリア

第9章 南米の分岐病変市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの分岐病変市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート
    • トルコ
    • エジプト

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 最近の動向
  • 製品上市
  • 合併と買収

第13章 世界の分岐病変市場：SWOT分析

第14章 競合情勢

  • Boston Scientific Corp.
  • Abbott Laboratories Inc.
  • Cardinal Health Inc.
  • Medtronic Plc
  • C. R. Bard, Inc.（Becton, Dickinson and Company）
  • Johnson & Johnson Services, Inc.
  • Spectranetics Corp（Philips Healthcare）
  • Terumo Medical Corp.
  • Poseidon Medical Inc.

第15章 戦略的提言

第16章 調査会社について・免責事項

目次
Product Code: 22390

Global Bifurcation Lesions Market was valued at USD 2.76 billion in 2024 and is expected to reach USD 4.02 Billion in the forecast period with a CAGR of 6.43% through 2030. The Global Bifurcation Lesions Market encompasses a specialized segment of the medical industry focused on the diagnosis and treatment of bifurcation lesions, which occur when a major artery divides into two smaller branches.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 2.76 Billion
Market Size 2030USD 4.02 Billion
CAGR 2025-20306.43%
Fastest Growing SegmentPeripheral
Largest MarketNorth America

The Global Bifurcation Lesions Market deals with medical devices, procedures, and therapies aimed at addressing the challenges posed by bifurcation lesions in blood vessels, particularly in coronary arteries. These lesions can restrict blood flow, leading to cardiovascular complications.

Key Market Drivers

Increasing Cardiovascular Disease Prevalence

The increasing prevalence of cardiovascular diseases (CVDs) serves as a significant market driver propelling the growth of the Global Bifurcation Lesions Market. Cardiovascular diseases, encompassing conditions like coronary artery disease, heart attacks, and angina, are a leading cause of morbidity and mortality globally. The World Health Organization (WHO) reports that CVDs are responsible for over 17 million deaths annually, making them the leading cause of death worldwide. As lifestyles become more sedentary, diets less healthy, and populations age, the burden of CVDs is projected to continue increasing. Bifurcation lesions are a subset of cardiovascular conditions in which plaque buildup or blockages occur at the junctions where major arteries split into smaller branches. Such lesions can lead to severe complications, including heart attacks and reduced blood flow to vital organs. As the prevalence of CVDs increases, so does the incidence of bifurcation lesions, driving the demand for specialized treatments. According to Centers for Disease Control and Prevention, Heart disease is the leading cause of death for both men and women, as well as for individuals across most racial and ethnic groups. Every 33 seconds, someone dies from cardiovascular disease. In 2022 alone, heart disease was responsible for 702,880 deaths, accounting for roughly one in every five deaths.

Key Market Challenges

Complexity of Bifurcation Lesion Treatment

Bifurcation lesions pose a unique set of challenges due to the branching of blood vessels. These complexities include variable lesion morphologies, side branch ostial stenosis, and the risk of restenosis at the bifurcation point. Treating these lesions requires specialized techniques, tools, and stents, which can be challenging for healthcare providers. Additionally, the need for expert knowledge and training in bifurcation lesion management can limit the number of physicians who can effectively perform these procedures, potentially slowing down market growth.

Regulatory and Reimbursement Hurdles

Medical devices and procedures in the cardiovascular field, including those used for bifurcation lesion treatment, are subject to stringent regulatory requirements and approvals. Obtaining regulatory clearance or approval can be a time-consuming and costly process. Furthermore, reimbursement policies vary by region, and reimbursement challenges can affect the adoption of newer and more advanced technologies. Limited or delayed reimbursement for these procedures can discourage healthcare providers from offering them, which can hinder market expansion.

Key Market Players

  • Boston Scientific Corp.
  • Abbott Laboratories Inc.
  • Cardinal Health Inc.
  • Medtronic Plc
  • C. R. Bard, Inc (Becton, Dickinson and Company)
  • Johnson & Johnson Services, Inc.
  • Spectranetics Corp (Philips Healthcare)
  • Terumo Medical Corp.
  • Poseidon Medical Inc

Report Scope:

In this report, the Global Bifurcation Lesions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bifurcation Lesions Market, By Application:

  • Peripheral
  • Coronary

Bifurcation Lesions Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwait
    • Turkey
    • Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bifurcation Lesions Market.

Available Customizations:

Global Bifurcation Lesions market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bifurcation Lesions Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Peripheral, Coronary)
    • 5.2.2. By Region
    • 5.2.3. By Company (2024)
  • 5.3. Market Map

6. North America Bifurcation Lesions Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bifurcation Lesions Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
    • 6.3.2. Canada Bifurcation Lesions Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
    • 6.3.3. Mexico Bifurcation Lesions Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application

7. Europe Bifurcation Lesions Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bifurcation Lesions Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
    • 7.3.2. United Kingdom Bifurcation Lesions Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
    • 7.3.3. Italy Bifurcation Lesions Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
    • 7.3.4. France Bifurcation Lesions Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
    • 7.3.5. Spain Bifurcation Lesions Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application

8. Asia-Pacific Bifurcation Lesions Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Bifurcation Lesions Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
    • 8.3.2. India Bifurcation Lesions Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
    • 8.3.3. Japan Bifurcation Lesions Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
    • 8.3.4. South Korea Bifurcation Lesions Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
    • 8.3.5. Australia Bifurcation Lesions Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application

9. South America Bifurcation Lesions Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Bifurcation Lesions Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
    • 9.3.2. Argentina Bifurcation Lesions Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
    • 9.3.3. Colombia Bifurcation Lesions Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application

10. Middle East and Africa Bifurcation Lesions Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Bifurcation Lesions Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
    • 10.3.2. Saudi Arabia Bifurcation Lesions Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
    • 10.3.3. UAE Bifurcation Lesions Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
    • 10.3.4. Kuwait Bifurcation Lesions Market Outlook
      • 10.3.4.1. Market Size & Forecast
        • 10.3.4.1.1. By Value
      • 10.3.4.2. Market Share & Forecast
        • 10.3.4.2.1. By Application
    • 10.3.5. Turkey Bifurcation Lesions Market Outlook
      • 10.3.5.1. Market Size & Forecast
        • 10.3.5.1.1. By Value
      • 10.3.5.2. Market Share & Forecast
        • 10.3.5.2.1. By Application
    • 10.3.6. Egypt Bifurcation Lesions Market Outlook
      • 10.3.6.1. Market Size & Forecast
        • 10.3.6.1.1. By Value
      • 10.3.6.2. Market Share & Forecast
        • 10.3.6.2.1. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Bifurcation Lesions Market: SWOT Analysis

14. Competitive Landscape

  • 14.1. Boston Scientific Corp.
    • 14.1.1. Business Overview
    • 14.1.2. Product & Service Offerings
    • 14.1.3. Recent Developments
    • 14.1.4. Key Personnel
    • 14.1.5. SWOT Analysis
    • 14.1.6. Financials (As Reported)
  • 14.2. Abbott Laboratories Inc.
  • 14.3. Cardinal Health Inc.
  • 14.4. Medtronic Plc
  • 14.5. C. R. Bard, Inc.(Becton, Dickinson and Company)
  • 14.6. Johnson & Johnson Services, Inc.
  • 14.7. Spectranetics Corp (Philips Healthcare)
  • 14.8. Terumo Medical Corp.
  • 14.9. Poseidon Medical Inc.

15. Strategic Recommendations

16. About Us & Disclaimer